Drug intelligence / Profile preview

MLS301

Development stage: Preclinical
Lead developer: MycoMedica
Modality: Small Molecules
Administration: Oral

Overview

MLS301 is an early-stage, low-dose psilocybin formulation under development by MycoMedica Life Sciences for the treatment of Obsessive-Compulsive Disorder (OCD). Psilocybin is a classic psychedelic tryptamine that acts as a prodrug to psilocin, which primarily targets and activates serotonin 5-HT2A and 5-HT1A receptors in the brain. By modulating serotonergic pathways, MLS301 aims to disrupt the rigid, repetitive cognitive patterns and neural circuitry associated with OCD, potentially offering rapid and sustained therapeutic relief with a low-dose paradigm designed to minimize hallucinogenic effects.

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR6 (5-hydroxytryptamine receptor 6)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on MLS301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MLS301.

Explore the full profile